Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00811-8
Abstract: Objectives: Anlotinib is an oral multi-kinase inhibitor that widely inhibits VEGFR, PDGFR, FGFR and c-kit. Previous researches have shown clinical antitumor activity of anlotinib in various cancers, including the gynecologic tumors. This investigator-initiated, single-arm, open-label,… read more here.
Keywords: plus chemotherapy; treatment; anlotinib plus; ovarian cancer ... See more keywords
Anlotinib plus chemotherapy for T790M‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14713
Abstract: This multicenter phase 1b/2 trial aimed to explore the maximum tolerated dose (MTD), activity, and safety of anlotinib plus chemotherapy in patients with T790M‐negative epidermal growth factor receptor (EGFR)‐mutant advanced nonsquamous non‐small cell lung cancer… read more here.
Keywords: t790m negative; plus chemotherapy; anlotinib plus; egfr mutant ... See more keywords
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s379269
Abstract: Objective This study was to investigate the effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft tissue sarcoma (STS). Methods Patients with previously treated metastatic STS who were administered… read more here.
Keywords: anlotinib plus; plus inhibitors; previously treated; patients previously ... See more keywords